Trillium Therapeutics : J.P. Morgan 34th Annual Healthcare Conference

PowerPoint Presentation

J.P. Morgan 34th Annual Healthcare Conference January 11-14, 2016

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, Trillium's ability to obtain financing to advance the products in its development portfolio; changing market conditions; the successful and timely completion of pre- clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in Trillium's ongoing quarterly and annual reporting. Forward-looking statements are made only as of the date of this presentation and except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investment Highlights

• Immuno-oncology company developing a next

  generation immune checkpoint inhibitor

• Lead program SIRPαFc targets CD47, a "do not eat" signal tumor cells exploit to escape destruction by the innate immune system

• Phase 1a/1b trial in patients with advanced hematologic malignancies ongoing

• Raised ~$85M (Since 12/2013) from premier US healthcare funds to support clinical development

Experienced Leadership & Veteran Board of Directors

MANAGEMENT

Executive	Title	Joined Trillium
Dr. Niclas Stiernholm	President & Chief Executive Officer	2002
Dr. Robert Uger	Chief Scientific Officer	2003
Dr. Eric Sievers	Chief Medical Officer	2015
Dr. Penka Petrova	Chief Development Officer	2003
Mr. James Parsons	Chief Financial Officer	2003
Ms. Elizabeth Wieland	Senior Director, Clinical Operations	2015

BOARD OF DIRECTORS

Executive	Affiliation
Dr. Calvin Stiller, Chair	Chair
Dr. Henry Friesen	Chair (former)
Dr. Niclas Stiernholm	CEO
Dr. Michael Moore	CEO (former)

Executive	Affiliation
Dr. Robert Kirkman	CEO
Dr. Thomas Reynolds	CMO (former)
Mr. Luke Beshar	CFO (former)